Compare Chevron Corp (CVX) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Chevron Corp vs BIO-TECHNE Corp — how do they compare? Chevron Corp trades at $211.98 (market cap $414.98B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Chevron Corp is far larger — about 36.5× BIO-TECHNE Corp's market cap, and Chevron Corp pays the higher dividend (3.37%). Which is the better fit depends on your goals — on Pluang, investors hold Chevron Corp for 101 Days and BIO-TECHNE Corp for 64 Days on average.
| CVX | TECH | |
|---|---|---|
Market Cap | $414.98B | $11.36B |
Volume | 7,575,112 | 5,390,331 |
Sector | Energy | Health |
52-Week High | $217.73 | $72.61 |
52-Week Low | $146.72 | $43.31 |
Typical Hold Time | 101 Days | 64 Days |
Enterprise Value | $443.52B | $11.39B |
Dividend Yield | 3.37% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CVX trades at $211.605, up 3.13% today, with a bullish technical signal and strong earnings beats in recent quarters. The stock is supported by robust cash flow from operations of $33.94B in 2025 and a dividend of $1.78 per share. However, revenue and net income have declined from 2022 peaks, with 2025 revenue at $184.43B and net income at $12.30B. Analyst consensus is bullish with a $208.31 price target, though geopolitical tensions and oil price volatility pose risks.
The outlook for CVX is cautiously optimistic, driven by high oil prices and strategic investments like the $13.8B Argentina project. Investment opportunities include a solid dividend yield and potential upside from production growth. Key risks are exposure to fluctuating oil prices, geopolitical instability affecting supply chains, and declining profit margins. Investors should weigh strong cash generation against cyclical industry pressures.
TECH trades at $72.45, near its 52-week high of $72.70 (Defense World, 2026-09-28), with a slight 0.11% decline over 24 hours. The stock shows a bullish technical signal, supported by moving averages, while fundamentals reveal a high P/E of 62.46 and net income margin of 14.97% for 2025. Recent news highlights shareholder approval of its acquisition by Merck KGaA at $73.00 per share (PRNewsWire, 2026-09-23), a key catalyst for near-term price action.
The outlook is mixed: the acquisition offers upside to the current price, but elevated valuation ratios pose risks if earnings growth falters. Analyst consensus is divided with 46% buy ratings, and net income volatility from 2022-2025 signals execution challenges. Investors should weigh the acquisition premium against fundamental sustainability in a competitive life sciences tools sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Chevron Corp
Chevron Corporation is an integrated energy company with operations in countries located around the world. The Company produces and transports crude oil and natural gas. Chevron also refines, markets, and distributes fuels, as well as is involved in chemical and mining operations, power generation, and energy services.
Read more on CVX →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
